Cargando…
Region-Specific Effects of Immunotherapy With Antibodies Targeting α-synuclein in a Transgenic Model of Synucleinopathy
Synucleinopathies represent a group of neurodegenerative disorders which are characterized by intracellular accumulation of aggregated α-synuclein. α-synuclein misfolding and oligomer formation is considered a major pathogenic trigger in these disorders. Therefore, targeting α-synuclein species repr...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6039792/ https://www.ncbi.nlm.nih.gov/pubmed/30022929 http://dx.doi.org/10.3389/fnins.2018.00452 |
_version_ | 1783338746456834048 |
---|---|
author | Kallab, Martin Herrera-Vaquero, Marcos Johannesson, Malin Eriksson, Fredrik Sigvardson, Jessica Poewe, Werner Wenning, Gregor K. Nordström, Eva Stefanova, Nadia |
author_facet | Kallab, Martin Herrera-Vaquero, Marcos Johannesson, Malin Eriksson, Fredrik Sigvardson, Jessica Poewe, Werner Wenning, Gregor K. Nordström, Eva Stefanova, Nadia |
author_sort | Kallab, Martin |
collection | PubMed |
description | Synucleinopathies represent a group of neurodegenerative disorders which are characterized by intracellular accumulation of aggregated α-synuclein. α-synuclein misfolding and oligomer formation is considered a major pathogenic trigger in these disorders. Therefore, targeting α-synuclein species represents an important candidate therapeutic approach. Our aim was to analyze the biological effects of passive immunization targeting α-synuclein and to identify the possible underlying mechanisms in a transgenic mouse model of oligodendroglial α-synucleinopathy. We used PLP-α-synuclein mice overexpressing human α-synuclein in oligodendrocytes. The animals received either antibodies that recognize α-synuclein or vehicle. Passive immunization mitigated α-synuclein pathology and resulted in reduction of total α-synuclein in the hippocampus, reduction of intracellular accumulation of aggregated α-synuclein, particularly significant in the spinal cord. Lowering of the extracellular oligomeric α-synuclein was associated with reduction of the density of activated iba1-positive microglia profiles. However, a shift toward phagocytic microglia was seen after passive immunization of PLP-α-synuclein mice. Lowering of intracellular α-synuclein was mediated by autophagy degradation triggered after passive immunization in PLP-α-synuclein mice. In summary, the study provides evidence for the biological efficacy of immunotherapy in a transgenic mouse model of oligodendroglial synucleinopathy. The different availability of the therapeutic antibodies and the variable load of α-synuclein pathology in selected brain regions resulted in differential effects of the immunotherapy that allowed us to propose a model of the underlying mechanisms of antibody-aided α-synuclein clearance. |
format | Online Article Text |
id | pubmed-6039792 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-60397922018-07-18 Region-Specific Effects of Immunotherapy With Antibodies Targeting α-synuclein in a Transgenic Model of Synucleinopathy Kallab, Martin Herrera-Vaquero, Marcos Johannesson, Malin Eriksson, Fredrik Sigvardson, Jessica Poewe, Werner Wenning, Gregor K. Nordström, Eva Stefanova, Nadia Front Neurosci Neuroscience Synucleinopathies represent a group of neurodegenerative disorders which are characterized by intracellular accumulation of aggregated α-synuclein. α-synuclein misfolding and oligomer formation is considered a major pathogenic trigger in these disorders. Therefore, targeting α-synuclein species represents an important candidate therapeutic approach. Our aim was to analyze the biological effects of passive immunization targeting α-synuclein and to identify the possible underlying mechanisms in a transgenic mouse model of oligodendroglial α-synucleinopathy. We used PLP-α-synuclein mice overexpressing human α-synuclein in oligodendrocytes. The animals received either antibodies that recognize α-synuclein or vehicle. Passive immunization mitigated α-synuclein pathology and resulted in reduction of total α-synuclein in the hippocampus, reduction of intracellular accumulation of aggregated α-synuclein, particularly significant in the spinal cord. Lowering of the extracellular oligomeric α-synuclein was associated with reduction of the density of activated iba1-positive microglia profiles. However, a shift toward phagocytic microglia was seen after passive immunization of PLP-α-synuclein mice. Lowering of intracellular α-synuclein was mediated by autophagy degradation triggered after passive immunization in PLP-α-synuclein mice. In summary, the study provides evidence for the biological efficacy of immunotherapy in a transgenic mouse model of oligodendroglial synucleinopathy. The different availability of the therapeutic antibodies and the variable load of α-synuclein pathology in selected brain regions resulted in differential effects of the immunotherapy that allowed us to propose a model of the underlying mechanisms of antibody-aided α-synuclein clearance. Frontiers Media S.A. 2018-07-04 /pmc/articles/PMC6039792/ /pubmed/30022929 http://dx.doi.org/10.3389/fnins.2018.00452 Text en Copyright © 2018 Kallab, Herrera-Vaquero, Johannesson, Eriksson, Sigvardson, Poewe, Wenning, Nordström and Stefanova. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neuroscience Kallab, Martin Herrera-Vaquero, Marcos Johannesson, Malin Eriksson, Fredrik Sigvardson, Jessica Poewe, Werner Wenning, Gregor K. Nordström, Eva Stefanova, Nadia Region-Specific Effects of Immunotherapy With Antibodies Targeting α-synuclein in a Transgenic Model of Synucleinopathy |
title | Region-Specific Effects of Immunotherapy With Antibodies Targeting α-synuclein in a Transgenic Model of Synucleinopathy |
title_full | Region-Specific Effects of Immunotherapy With Antibodies Targeting α-synuclein in a Transgenic Model of Synucleinopathy |
title_fullStr | Region-Specific Effects of Immunotherapy With Antibodies Targeting α-synuclein in a Transgenic Model of Synucleinopathy |
title_full_unstemmed | Region-Specific Effects of Immunotherapy With Antibodies Targeting α-synuclein in a Transgenic Model of Synucleinopathy |
title_short | Region-Specific Effects of Immunotherapy With Antibodies Targeting α-synuclein in a Transgenic Model of Synucleinopathy |
title_sort | region-specific effects of immunotherapy with antibodies targeting α-synuclein in a transgenic model of synucleinopathy |
topic | Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6039792/ https://www.ncbi.nlm.nih.gov/pubmed/30022929 http://dx.doi.org/10.3389/fnins.2018.00452 |
work_keys_str_mv | AT kallabmartin regionspecificeffectsofimmunotherapywithantibodiestargetingasynucleininatransgenicmodelofsynucleinopathy AT herreravaqueromarcos regionspecificeffectsofimmunotherapywithantibodiestargetingasynucleininatransgenicmodelofsynucleinopathy AT johannessonmalin regionspecificeffectsofimmunotherapywithantibodiestargetingasynucleininatransgenicmodelofsynucleinopathy AT erikssonfredrik regionspecificeffectsofimmunotherapywithantibodiestargetingasynucleininatransgenicmodelofsynucleinopathy AT sigvardsonjessica regionspecificeffectsofimmunotherapywithantibodiestargetingasynucleininatransgenicmodelofsynucleinopathy AT poewewerner regionspecificeffectsofimmunotherapywithantibodiestargetingasynucleininatransgenicmodelofsynucleinopathy AT wenninggregork regionspecificeffectsofimmunotherapywithantibodiestargetingasynucleininatransgenicmodelofsynucleinopathy AT nordstromeva regionspecificeffectsofimmunotherapywithantibodiestargetingasynucleininatransgenicmodelofsynucleinopathy AT stefanovanadia regionspecificeffectsofimmunotherapywithantibodiestargetingasynucleininatransgenicmodelofsynucleinopathy |